Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Sponsor: BRIM Biotechnology Inc.
Summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Official title: An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-07-31
Completion Date
2025-11-30
Last Updated
2024-10-28
Healthy Volunteers
No
Conditions
Interventions
BRM424 Ophthalmic Solution - Dose1
A topical drop of BRM424 ophthalmic solution.
BRM424 Ophthalmic Solution - Dose2
A topical drop of BRM424 ophthalmic solution.
Locations (1)
Wilmington Eye
Leland, North Carolina, United States